Holen Sie sich die Stockscreener-App
7.84
0.51%
0.04
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat
What is HC Wainwright’s Forecast for COGT FY2024 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for COGT Earnings - MarketBeat
Needham Downgrades Cogent Biosciences (COGT) - MSN
Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Receives “Buy” Rating from Needham & Company LLC - Defense World
Cogent Biosciences Announces Updated Clinical Results from Summit, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Given Buy Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences Announces Updated Clinical Results from - GlobeNewswire
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Quantisnow
Cogent Biosciences Announces Positive Updated Data from - GlobeNewswire
Cogent's Bezuclastinib Shows Remarkable 83% Response Rate in Advanced Mastocytosis Trial - StockTitan
(COGT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Fmr LLC Has $89.85 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Reduced by Redmile Group LLC - MarketBeat
Bank of Montreal Can Takes $3.14 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Intech Investment Management LLC Buys Shares of 28,424 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Raises Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
COGT (Cogent Biosciences) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Walleye Capital LLC Acquires Shares of 557,326 Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Eventide Asset Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus PT from Brokerages - Defense World
(COGT) Trading Advice - Stock Traders Daily
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World
What is Leerink Partnrs' Estimate for COGT FY2024 Earnings? - MarketBeat
FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - Defense World
Trend Tracker for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat
Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World
Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat
Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat
FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat
COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Kynam Capital Management, LP Reduces Stake in Cogent Biosciences Inc - GuruFocus.com
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com
Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
Cogent Biosciences Reports Strong Pipeline Progress, $346M Cash Position Despite Q3 Losses | COGT Stock News - StockTitan
Creative Planning Buys 3,272 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences’ (COGT) Buy Rating Reaffirmed at HC Wainwright - Defense World
FMR LLC Acquires Additional Shares in Cogent Biosciences Inc - GuruFocus.com
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):